Androgenetic Alopecia Clinical Trials 2023

Androgenetic Alopecia Clinical Trials 2023

Androgenetic Alopecia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in androgenetic alopecia clinical trials today.

Trials for Alopecia Areata Patients

Trials for Male Pattern Baldness Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to androgenetic alopecia

What are the top hospitals conducting androgenetic alopecia research?

Hair loss is a common concern for many individuals, particularly those experiencing androgenetic alopecia. Fortunately, several top hospitals are dedicated to unraveling the mysteries of this condition through clinical trials. In New york City, the Icahn School of Medicine at Mount Sinai leads the way with six ongoing trials focused on androgenetic alopecia and a commendable record of 15 previous studies. Their first recorded trial dates back to 2015, showcasing their commitment to finding effective treatments for hair loss. Meanwhile, ForCare Clinical Research in Tampa has made significant strides since initiating their inaugural trial in 2018. Currently conducting five active trials, they have already completed eight investigations into androgenetic alopecia.

The Dawes Fretzin Clinical Research Group LLC in Indianapolis also deserves recognition for its efforts in advancing our understanding of this condition. With four ongoing clinical trials and ten all-time studies under their belt since starting research in 2016, they continue to impact the field positively. Additionally entering the scene is NW Dermatology & Research Center LLC based in Portland where four active androgenetic alopecia trials contribute towards overall scientific knowledge; however theirs remains relatively new having only begun documenting these investigations as recently as 2015.

Notably joining this group is Memorial Sloan Kettering Cancer Center once again demonstrating its versatility by delving into dermatological conditions such as androgenetic alopecia - three ongoing clinical tests further building upon three former experiments from inception during year 2014.These esteemed institutions symbolize hope for individuals grappling with hair loss due to genetic factors like male or female pattern baldness.For them it represents an opportunity not just restore confidence but open doors treatment options that may revolutionize future possibilities- highlighting how medical advancements can reshape lives beyond conventional expectations

Which are the best cities for androgenetic alopecia clinical trials?

For individuals seeking clinical trials for androgenetic alopecia, several cities emerge as frontrunners in research. New york, New York, leads the way with 14 active trials investigating treatments like Dupilumab, CTP-543, and Treatment Group. Portland, Oregon closely follows with 14 ongoing studies focusing on interventions such as Baricitinib and TDM-105795 topical solution. San Antonio, Texas ranks third with 13 active trials studying CTP-543 and Deucravacitinib Dose 1 among others. Across the country in Minneapolis, Minnesota, there are 12 ongoing trials examining PF-06651600 and Baricitinib alongside other potential treatments. Finally, Houston,Texas offers 11 active trials exploring options like Baricitinib and Deucravacitinib Dose 1 along with innovative interventions such as PAXMAN Orbis Scalp Cooler. These cities provide promising opportunities for those interested in participating in cutting-edge clinical research for combating androgenetic alopecia.

Which are the top treatments for androgenetic alopecia being explored in clinical trials?

Clinical trials are actively exploring various treatment options for androgenetic alopecia, a common form of hair loss. Among the top treatments being investigated are:

  • PF-06651600: With three active trials dedicated to androgenetic alopecia, this drug has shown promise since its listing in 2016.
  • Baricitinib: Listed in 2018, baricitinib is currently involved in two ongoing clinical trials for treating androgenetic alopecia.
  • Dupilumab: Also listed in 2018, dupilumab is being studied in two active trials to determine its effectiveness against androgenetic alopecia.

As researchers delve deeper into these potential therapies, there is hope that new solutions may emerge to address the challenges posed by androgenetic alopecia.

What are the most recent clinical trials for androgenetic alopecia?

Exciting advancements in the field of androgenetic alopecia treatment are emerging from recent clinical trials. ADX-914, a promising experimental drug, has shown potential in Phase 2 studies for combating this condition. Farudodstat, Dupilumab, Oral Minoxidil, and TDM-105795 topical solution have also undergone Phase 2 trials with encouraging results. These innovative therapies offer new hope for individuals seeking effective treatments to address androgenetic alopecia's impact on hair loss. With further research and development underway, there is optimism for improved solutions to combat this common condition in the near future.

What androgenetic alopecia clinical trials were recently completed?

Several noteworthy clinical trials for androgenetic alopecia have recently reached completion, presenting promising developments in the search for effective treatments. In April 2022, LEO Pharma concluded a trial investigating Delgocitinib cream. Likewise, in February 2022, Suzhou Kintor Pharmaceutical Inc.'s GT20029 Gel study and Technoderma Medicines Inc.'s TDM-105795 trial were finished. Another TDM-105795 trial by Technoderma Medicines Inc., along with Concert Pharmaceuticals' CTP-543 investigation, wrapped up their respective studies in April 2021 and February 2021. Earlier milestones include Pfizer's Etrasimod trial completed in July 2020 and the University of Arizona's Keratinocyte growth factor study finalized in April 2020. These achievements underscore the dedication of researchers aiming to address the challenges posed by androgenetic alopecia while offering hope to individuals affected by this condition.